Physician profile
Rabih Nayfe
NPI 1760823553
$21,096.96
in general payments reported to CMS, 2019-2025
52 companies · $3,522 in 2025
The $3,522 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,769 · 2020: $1,777 · 2021: $2,251 · 2022: $3,405 · 2023: $4,473 · 2024: $3,901 · 2025: $3,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,841.03 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,385.38 | 2019-2025 | |
| Amgen INC. | $3,321.94 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $2,615.63 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,775.63 | 2020-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,004.38 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $639.62 | 2019-2025 | Orencia |
| Radius Health, INC. | $563.83 | 2020-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $514.13 | 2021-2023 | Saphnelo |
| Horizon Therapeutics Plc | $364.31 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $362.10 | 2019-2024 | Benlysta |
| Janssen Pharmaceuticals, INC | $335.40 | 2019-2022 | |
| Antares Pharma, INC. | $277.74 | 2019-2022 | |
| Pfizer INC. | $231.50 | 2019-2025 | |
| Lilly USA, LLC | $215.64 | 2019-2024 | Jardiance, Baqsimi, Lyumjev |
| Genentech USA, INC. | $184.56 | 2020-2025 | Actemra |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabih Nayfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.